Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI - Top-Institutions - MDSpire

Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI

  • By

  • Ran Yan

  • Wakana Murakami

  • Shabnam Mortazavi

  • Tiffany Yu

  • Fang-I. Chu

  • Stephanie Lee-Felker

  • Kyunghyun Sung

  • April 29, 2024

  • 0 min

Share

Top Institutions in Radiology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Breast Imaging
    • Breast Cancer Genetics
    • Oncology

  • #2

    Dana-Farber Cancer Institute / Brigham and Women's Hospital
    Dana-Farber Cancer Institute / Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Breast Imaging
    • Cancer Genetics
    • Radiology

  • #3

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Breast Imaging
    • Cancer Prevention
    • Genetics

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Breast Imaging
    • Radiology
    • Genetic Epidemiology

  • #5

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Breast Imaging
    • Oncology
    • Genetics

Original Source(s)

Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI

  • by Ran Yan, Wakana Murakami, Shabnam Mortazavi, Tiffany Yu, Fang-I. Chu, Stephanie Lee-Felker, Kyunghyun Sung

  • April 29, 2024

Related Content

Enhanced Prediction of HER2 Status in Breast Cancer through the Integration of Intratumoral and Peritumoral Radiomic Features from DCE-MRI

Diagnostic value of multimodal ultrasound imaging in triple-negative breast cancer

Evaluating Ultrasound as a Predictor of Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Systematic Review and Meta-Analysis